PROTAD Compounds Degrading BCR-ABL to Overcome TKI Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic myeloid leukemia (CML) relying on tyrosine kinase inhibitors (TKIs) face challenges with long-term medication requirements and secondary drug resistance due to the persistence of leukemic stem cells, which are not effectively cleared by TKIs alone.
Innovation Solution
Development of PROTAD compounds that target and degrade the BCR-ABL fusion protein by recruiting Von Hippel Lindau (VHL) or Cereblon (CRBN) E3 ubiquitin ligases, utilizing specific molecular structures to facilitate protein degradation through the ubiquitin-proteasome system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tyrosine kinase inhibitors (TKIs) are used to treat CML, then the proliferation of BCR-ABL positive leukemia cells is inhibited and clinical remission is achieved, but leukemic stem cells are not effectively cleared requiring long-term medication and leading to secondary drug resistance
Solution Approach 1:
The invention extracts and targets the specific BCR-ABL fusion protein present in leukemic stem cells using PROTAD compounds. By designing molecules that specifically bind to and degrade BCR-ABL through recruitment of VHL E3 ubiquitin ligase, the treatment directly eliminates the root cause in stem cells rather than merely inhibiting proliferation, thereby achieving curative intent without long-term maintenance therapy
Solution Approach 2:
The invention changes the mechanism of action from kinase inhibition (TKI) to protein degradation (PROTAD). This parameter change in the molecular mechanism allows for complete elimination of BCR-ABL protein in leukemic stem cells, transforming the treatment from chronic suppression to potential cure, thus reducing medication duration
2Reliability
If tyrosine kinase inhibitors (TKIs) are used to treat CML, then the proliferation of BCR-ABL positive leukemia cells is inhibited, but secondary drug resistance occurs due to persistence of leukemic stem cells
Solution Approach 1:
The invention specifically targets and extracts the BCR-ABL fusion protein from leukemic stem cells using PROTAD compounds. By recruiting VHL E3 ubiquitin ligase to degrade BCR-ABL, the treatment eliminates the molecular target that drives both active leukemia and dormant stem cell persistence, thereby preventing the development of secondary drug resistance
Solution Approach 2:
The invention performs preliminary action by completely degrading BCR-ABL protein in leukemic stem cells before they can enter a resistant or dormant state. This proactive degradation approach prevents the emergence of drug-resistant clones that would otherwise develop during prolonged TKI therapy
3Reliability
If traditional chemotherapy or interferon treatment is used, then some antitumor effect is achieved, but the response is poor and side effects are significant with inability to fundamentally eliminate the pathogenic BCR-ABL gene
Solution Approach 1:
The invention introduces PROTAD compounds as a new intermediary mechanism that bridges the gap between chemotherapy and genetic cure. These compounds act as molecular mediators that recruit the cell's own ubiquitin-proteasome system to degrade BCR-ABL, providing targeted therapy with fewer side effects and the potential for fundamental elimination of the pathogenic protein
Solution Approach 2:
The invention replaces the non-specific mechanical destruction of chemotherapy with precise molecular degradation. PROTAD compounds selectively target BCR-ABL protein for degradation through the ubiquitin-proteasome pathway, substituting the blunt instrument of chemotherapy with a precision molecular mechanism that spares healthy cells and reduces side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PROTAD compounds effectively degrade BCR-ABL proteins, potentially addressing the issue of long-term medication needs and drug resistance by targeting the root cause of CML, offering a new approach to eliminate leukemic stem cells.
Implementation Method 1
utilizing specific molecular structures to facilitate protein degradation through the ubiquitin-proteasome system
Data Source
AI summary
The present disclosure provides a compound of formula (I) targeting and degrading BCR-ABL protein and its use in the field of antitumor. The compound of formula (I) shows degradation and inhibitory effects on BCR-ABL target protein, which is mainly comprised of four moieties, wherein the first moiety (BCR-ABL-TKIs) is compound moiety with BCR-ABL tyrosine kinase inhibited activity; the second moiety (the LIN) is link units; the third moiety (the ULM) is a small molecule ligand for VHL or CRBN proteases with ubiquitination; and the four moiety (the group A) is carbonyl group that covalently binds to BCR-ABL-TKIs and LIN, and the LIN is further covalently bonded to ULM. A series of compounds designed and synthesized by the present disclosure shows extensive pharmacological effective, which function to degrade BCR-ABL protein and inhibit BCR-ABL effective, and can be utilized for treating relevant tumor.